Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | CFTR | P13569 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601439 | 0.94 | MAOB (0.47) | ALDH1A1POLBMAOBPGRCFTR | |
| SCHEMBL6601713 | 0.89 | ALDH1A1 (0.42) | ALDH1A1POLBMAOBPGRCFTR | |
| SCHEMBL6604786 | 0.88 | TSHR (0.47) | ALDH1A1POLBKMT2AMEN1MAPK1 | |
| SCHEMBL6605509 | 0.88 | ABL1 (0.50) | ALDH1A1POLBABL1MAOBCFTR | |
| SCHEMBL6602175 | 0.88 | PDE4D (0.47) | ALDH1A1POLB | |
| SCHEMBL7645940 | 0.87 | ALDH1A1 (0.46) | ALDH1A1POLBABL1MAOBPGR | |
| SCHEMBL6605449 | 0.87 | ALDH1A1 (0.48) | ALDH1A1POLBABL1MAOBPGR | |
| SCHEMBL6600745 | 0.87 | MAOB (0.48) | ALDH1A1POLBMAOBPGRGAA | |
| SCHEMBL6602107 | 0.86 | NPC1 (0.48) | ALDH1A1POLBABL1PGRCFTR | |
| SCHEMBL6605418 | 0.86 | ALDH1A1 (0.42) | ALDH1A1POLBMAOBPGRCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6479494-B1 | THEY INHIBIT SELECTIVELY PHOSPHODIESTERASE IV, WHICH CAUSES AN INCREASE OF THE INTRACELLULAR CAMP LEVEL AS CAMP INHIBITS BONE DECREASING CELLS AND STIMULATES BONE INCREASING CELLS FOR TREATMENT OF OSTEOPOROSIS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-11-12 | — | — | US | disclosed |
| EP-1143944-A3 | USE OF ARYLALKANOYLPYRIDAZINES | MERCK PATENT GmbH (DE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1143944-A2 | USE OF ARYLALKANOYLPYRIDAZINES | MERCK PATENT GmbH (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000059484-A2 | USE OF ARYLALKANOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2000-10-12 | — | — | WO | disclosed |
| US-6107295-A | Arylalkanoyl pyridazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-22 | — | — | US | disclosed |